Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Tuberculosis and HIV news

Show

From To
WHO announces landmark changes in MDR-TB treatment regimens

Major improvement in treatment outcomes and quality of life of patients with multidrug-resistant tuberculosis (MDR-TB) are expected, following key changes in MDR-TB treatment announced by WHO today.

Published
10 hours ago
From
World Health Organization
MSF applauds World Health Organization's recommendation of improved tuberculosis treatment options

Médecins Sans Frontières (MSF) today welcomed the new World Health Organization (WHO) recommendations for improved treatment for people with drug-resistant tuberculosis (DR-TB), prioritising the use of several oral drugs, including the newer drug bedaquiline, and minimising the use of drugs that must be injected.

Published
12 hours ago
From
ReliefWeb
South Africa strikes deal on new TB drug as WHO revisits guidance

The World Health Organization could soon start promoting a new tuberculosis drug that is now more affordable after South Africa brokered a deal with a pharmaceutical company to slash the price by half.

Published
13 August 2018
From
Devex
The 2018 Pipeline Report

Welcome to the 2018 Pipeline Report, Treatment Action Group’s annual review of therapeutics, diagnostics, vaccines, and preventive technologies in development for HIV, hepatitis C virus (HCV), and tuberculosis, along with immune-based and gene therapies and research toward a cure for HIV.

Published
24 July 2018
From
TAG
AIDS 2018: Price of bedaquiline drops in South Africa, will replace injectable TB drugs, Minister of Health announces

South Africa has signed a deal with bedaquiline manufacturer Jannsen pharmaceuticals to drop the price of the drug from $750 for a full course to $400, for the next eight months,Minister of Health Aaron Motsoaledi announced here today.

Published
23 July 2018
From
Science Speaks
Higher doses of rifampin appear more effective in fighting TB without increasing risk of adverse events

Higher daily doses of rifampin, a cornerstone of tuberculosis treatment, killed more TB bacteria in sputum cultures, and the higher doses did so without increasing the adverse effects of treatment, according to a randomized controlled trial published online in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

Published
29 June 2018
From
Eurekalert Inf Dis
High rates of HIV and diabetes raise the risk of TB for South Africans

The Yale-led research team analyzed health data on more than 7,000 patients screened for both chronic and infectious diseases. After adjusting for demographic and socioeconomic factors, the researchers found that people with either HIV or diabetes were more likely to also have TB. They also discovered that having both diseases further compounded the risk for developing TB symptoms. This is one of the first studies to demonstrate the possible synergism between HIV and diabetes to increase risk of TB, the researchers said.

Published
20 June 2018
From
Yale News
All-access for blockbuster TB drug in South Africa

The country made history on Monday when the health department announced that all drug-resistant tuberculosis (DR-TB) patients will be eligible to receive the new medicine, bedaquiline. “The Department of Health’s [DoH] commitment on bedaquiline is momentous globally and marks a new era of DR-TB management where we are really prioritising the patient,” Doctors Without Borders’ Dr Anja Reuters told Health-e News.

Published
19 June 2018
From
Health-e
Could a New Universal Tuberculosis Regimen Help End the TB Pandemic?

As tuberculosis (TB) is the world's most lethal infectious disease, there is an urgent need to improve the treatment of this bacterial infection. One approach under consideration is the institution of a universal or “pan-TB” regimen comprising new agents capable of treating multidrug-resistant (MDR) and even extensively drug-resistant (XDR) TB.

Published
29 May 2018
From
Infectious Disease Advisor
Scientists join forces to fight TB and HIV in EUR 12.9 million TREATS trial

The EUR 12.9 million project, featuring a number of international institutions including Imperial College London, will measure the impact of combined tuberculosis (TB) and HIV interventions on over one million people in communities across Zambia and South Africa.

Published
01 May 2018
From
Imperial College London
← First12345...65Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.